Regulus Therapeutics Inc. (RGLS)
Company Info
Highlights
$549.03M
-$0.68
-0.04
$340.00K
$81.00K
-$48.08M
$0.83 - $8.20
$8.80
4.97%
1.08
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Regulus Therapeutics Inc. (RGLS) returned 402.53% year-to-date (YTD) and 272.77% over the past 12 months. Over the past 10 years, RGLS returned -41.37% annually, underperforming the S&P 500 benchmark at 10.85%.
RGLS
402.53%
135.61%
384.15%
272.77%
36.82%
1.15%
-41.37%
^GSPC (Benchmark)
0.51%
6.15%
-2.00%
12.92%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of RGLS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -36.71% | 35.00% | 29.63% | 356.00% | -0.50% | 402.53% | |||||||
| 2024 | -0.78% | 15.75% | 95.92% | -20.14% | -0.43% | -22.05% | 0.84% | -6.67% | -6.55% | -7.01% | 10.27% | -1.86% | 23.44% |
| 2023 | 5.11% | -6.94% | -36.75% | 57.52% | -2.62% | 13.08% | -4.76% | 11.43% | -12.18% | -11.68% | 8.26% | -2.29% | -6.57% |
| 2022 | -21.68% | -8.76% | 32.39% | -32.38% | 42.18% | -27.75% | -22.22% | -11.80% | 19.72% | -8.82% | 10.32% | -19.88% | -56.51% |
| 2021 | 2.96% | -10.79% | 25.81% | -10.90% | -29.04% | -17.56% | -13.43% | 10.16% | -10.94% | -33.19% | -16.02% | -18.71% | -76.67% |
| 2020 | 21.35% | -31.23% | -37.93% | 10.63% | 47.06% | -9.13% | 3.10% | -24.57% | -3.02% | -8.37% | 33.78% | 114.25% | 51.69% |
| 2019 | 1.01% | 37.23% | -20.93% | 12.75% | 2.61% | 5.93% | -51.11% | 2.21% | 15.27% | -5.54% | 22.04% | 7.23% | -4.36% |
| 2018 | 14.42% | -6.72% | -35.36% | -8.71% | 11.53% | -9.76% | -57.16% | -17.95% | -14.72% | -25.35% | -9.04% | -42.20% | -92.54% |
| 2017 | -46.67% | -12.50% | 57.14% | -6.06% | -9.68% | -29.60% | 6.53% | -4.76% | 25.00% | -20.00% | -9.01% | 14.30% | -53.78% |
| 2016 | -33.72% | 13.67% | 5.48% | -15.73% | 5.14% | -52.93% | 23.53% | -11.20% | 4.10% | -16.67% | -10.91% | -8.16% | -74.20% |
| 2015 | 19.39% | -3.29% | -8.53% | -25.91% | 12.51% | -22.38% | -25.18% | 1.59% | -21.49% | 1.68% | 51.43% | -13.41% | -45.64% |
| 2014 | 23.14% | 23.41% | -19.68% | -20.95% | -5.61% | 19.47% | -20.52% | 7.67% | -0.73% | 192.24% | -6.11% | -14.41% | 117.05% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 95, RGLS is among the top 5% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Regulus Therapeutics Inc. (RGLS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Regulus Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Regulus Therapeutics Inc. was 99.97%, occurring on Mar 27, 2023. The portfolio has not yet recovered.
The current Regulus Therapeutics Inc. drawdown is 99.70%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.97% | Nov 10, 2014 | 2108 | Mar 27, 2023 | — | — | — |
| -53.26% | Jul 12, 2013 | 208 | May 8, 2014 | 116 | Oct 22, 2014 | 324 |
| -25.98% | Jan 3, 2013 | 8 | Jan 14, 2013 | 40 | Mar 13, 2013 | 48 |
| -16.39% | Apr 1, 2013 | 23 | May 1, 2013 | 19 | May 29, 2013 | 42 |
| -15.76% | Oct 26, 2012 | 33 | Dec 14, 2012 | 3 | Dec 19, 2012 | 36 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Regulus Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Regulus Therapeutics Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 43.4% positive surprise.
Valuation
The Valuation section provides an overview of how Regulus Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for RGLS compared to other companies in the Biotechnology industry. RGLS currently has a PEG ratio of -0.0. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for RGLS relative to other companies in the Biotechnology industry. Currently, RGLS has a P/S ratio of 7.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RGLS in comparison with other companies in the Biotechnology industry. Currently, RGLS has a P/B value of 7.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |